Convergent Therapeutics, Inc.

- CONV01-α is an actinium-225 labeled radioantibody with proven efficacy and safety in multiple Phase 1/2 trials in prostate cancer patients - Convergent Therapeutics will conduct Phase 2 clinical trials in 2024 preparing for a registrational program in 2025 CAMBRIDGE, Mass., April 2, 2024 /PRNewswire/ -- Convergent Therapeutics Inc., a clinical stage biotechnology company focused on developing next generation radiopharmaceutical therapies for the treatment of prostate cancer and other cancers, today announced that the U.S. Food and Drug Administration ("FDA") has cleared the investigational new drug ("IND") application for CONV01-α, its lead candidate for the treatment of patients with advanced prostate cancer. "Receiving clearance of our IND is a significant milestone for Convergent Therapeutics," said Convergent's Co-founder and CEO, Philip Kantoff, MD. "While we have already treated well over 100 prostate cancer patients in the context of investigator INDs, this new IND will allow us to rapidly advance CONV01-α into Phase 3 studies and expand the scope of clinical development of CONV01-α as a monotherapy and in combination with other cancer therapies." In a multi-dose, dose escalation study conducted in advanced prostate cancer patients, CONV01-α demonstrated a prostate-specific antigen decline of 50% (PSA50) in 67% of patients and a PSA decline of 90% (PSA90) in 27% of patients and was well tolerated.1 Ongoing studies suggest CONV01-α may be highly effective when used alone or in combination with other cancer therapies. "Importantly, patients also showed minimal side effects in Phase 1/2 trials. CONV01-α's ideal biodistribution delivers potent alpha particles while avoiding immediate and significant salivary gland toxicity as well as the potential delayed renal toxicity," said Neil Bander, MD, Convergent's Co-founder and CSO. "CONV01-α's design increases delivery of tumor-killing radiation to malignant cells while greatly reducing both off-tumor effects and the amount of radiation delivered per dose, thereby improving both treatment efficacy and safety." About CONV01-α CONV01-α, Convergent's alpha emitting radioantibody, combines the precision and pharmacokinetics of antibodies with the tumor-killing potential of alpha emitting radionuclides. Specifically, CONV01-α uses a humanized monoclonal antibody targeted at prostate-specific membrane antigen (PSMA) which is highly overexpressed in prostate cancer cells. Since PSMA is a validated target, several therapeutics are directed at this antigen and CONV01-α is differentiated by its use of both an antibody and alpha emitter. CONV01-α is linked to a powerful radionuclide called 225Ac, which releases alpha particles which kill cancer cells through DNA double strand breaks. Unlike other radioactive sources, alpha particles deliver high-energy radiation over very short distances, thereby minimizing radiation exposure to healthy neighboring cells and tissues. Pairing highly selective antibodies with such a powerful yet precise payload offers the ideal combination to treat many types of cancers. About Convergent Therapeutics, Inc. Convergent Therapeutics Inc. is a clinical-stage biotechnology company focused on developing tumor-selective alpha radioantibodies to target cancer. The company was founded by world-renowned experts in clinical care and research, drug development and cancer biology and its proprietary platform is licensed from Cornell University. In harnessing the selectivity of antibodies and tumor-destructive potential of alpha radioisotopes, Convergent's radioantibodies precisely target cancer cells with potent, localized radiation. For more information, please visit and follow us on Twitter and LinkedIn. 1Nauseef, J. T., et al. Abstract CT014: Phase I dose-escalation study of fractionated dose 225AC J591 for metastatic castration resistant prostate cancer. Cancer Research. 2023: 83(8_Supplement). SOURCE Convergent Therapeutics

CAMBRIDGE, Mass., March 4, 2024 /PRNewswire/ -- Convergent Therapeutics Inc., a clinical stage biotechnology company focused on developing next generation radiopharmaceutical therapies for prostate and other cancers, today announced the appointment of Scott Myers as Chairman of its Board of Directors. Mr. Myers previously served as President and Chief Executive Officer of Viridian in 2023, and prior to that, he was the Chief Executive Officer of AMAG Technology, purchased by Covis Pharmaceuticals, SA in November of 2020. Prior to 2020, Mr. Myers served as both Chairman and Chief Executive Officer of Rainier Therapeutics, a private, clinical-stage biotechnology company focused on metastatic bladder cancer that was purchased by Fusion Pharmaceuticals in March of 2020. Prior to joining Rainier, Mr. Myers served as Chief Executive Officer, President and as a director of Cascadian Therapeutics Inc. prior to its acquisition by Seattle Genetics in March of 2018. Mr. Myers also served as Chief Executive Officer of Aerocrine AB, a medical device company from 2011 to 2015 prior to its acquisition by Circassia. "Speaking on behalf of Convergent's Board of Directors and our leadership team, I am delighted that Scott agreed to join our Board as Chair," said Dr. Philip Kantoff, Co-Founder and CEO of Convergent. "Scott brings an enormous amount of experience and expertise as both a Chief Executive Officer, as well as a board member and chair in numerous life science companies." Mr. Myers currently serves as the Chairman of the Board of Dynavax Technologies, a commercial stage vaccine company. Mr. Myers also serves as Chairman of the Board of Directors of Ironshore Pharmaceuticals, a private, commercial stage ADHD company. About Convergent Therapeutics, Inc. Convergent Therapeutics Inc. is a clinical-stage biotechnology company focused on developing next-generation radiopharmaceutical therapies for prostate and other cancers. The company's proprietary technology was developed by Dr. Neil Bander, Professor of Urologic Oncology at Weill Cornell Medicine, and licensed to Convergent by Cornell University. CONV01-α, a monoclonal antibody conjugated to actinium-225 (Ac-225), a radioactive alpha particle emitter, was specifically designed to bind to the prostate-specific membrane antigen (PSMA). A key functional feature of CONV01-α is that once bound to PSMA, it becomes internalized, delivering its powerful radioactive payload directly into prostate cancer cells while minimizing damage to surrounding healthy tissue. CONV01-α has the potential to be the first Ac-225 radioantibody approved for use in prostate cancer treatment. For more information, please visit and follow us on Twitter and LinkedIn. SOURCE Convergent Therapeutics

Radiopharmaceutical biotech Ratio Therapeutics has raised a $50 million Series B to bring its first therapeutic into the clinic, it said Wednesday morning. The biotech has now raised a total of $90 million since its founding in mid-2021. Based in Boston’s Seaport District, the biotech unveiled itself in June 2022 and has already inked collaborations with Bayer, Merck and Lantheus. Radiopharma companies have been in the news with considerably more frequency in recent months with two key acquisitions by Eli Lilly and Bristol Myers Squibb, and financing rounds rolling in for a string of startups, like Artbio , Convergent Therapeutics and Abdera Therapeutics . Bristol Myers invested in Ratio’s Series B. The expanding market is also causing CDMOs to iron out supply chain bumps and configure access to raw materials.